Dr. Reddy's Laboratories ( RDY) sank 2% early Monday despite hitting a third-quarter earnings triple.

The generic drugmaker earned 1.88 billion rupees, or $43 million. The company earned $14 million a year ago.

Revenue reached $350 million, up from $134 million a year ago.

Revenue from generic drugs was 7.68 billion rupees in the company's fiscal third quarter, compared with 831 million rupees a year ago, thanks to strong sales in North America and Europe. International sales of the company's branded drugs were 1.6 billion rupees, up 18% from a year ago thanks to sales in Russia and Central and Eastern Europe.

"For the first time in the history of Dr. Reddy's, we have crossed USD 1 billion in revenues," said Dr. Reddy's. "Dr. Reddy's has grown into a vertically integrated global pharmaceutical company with activities spanning the entire pharmaceutical value chain."

The stock fell 39 cents to $18.19.

More from Stocks

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Micron Shares Soar; Chipmaker Is 'Managing for Profitability' Now, Says Analyst

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Facebook CEO Mark Zuckerberg Deflects Tough Questions From European Parliament

Facebook CEO Mark Zuckerberg Deflects Tough Questions From European Parliament